Literature DB >> 7475041

Systemic and coronary hemodynamic actions and left ventricular functional effects of levosimendan in conscious dogs.

C P Harkin1, P S Pagel, J P Tessmer, D C Warltier.   

Abstract

We examined the effects of levosimendan, a new myofilament Ca2+ sensitizer with phosphodiesterase (PDE)-inhibiting properties, on systemic and coronary hemodynamics and left ventricular (LV) systolic and diastolic function in conscious dogs with intact and blocked autonomic nervous system (ANS) reflexes. Twenty experiments were conducted in 10 dogs chronically instrumented for measurement of aortic and LV pressure, the peak rate of increase and decrease in LV pressure (+dP/dtmax and -dP/dtmin), subendocardial segment length, diastolic coronary blood flow (CBF) velocity, and cardiac output (CO). The slope (Mw) of the regional preload recruitable stroke work relation was used to assess myocardial contractility. Diastolic function was evaluated by -dP/dtmin, a time constant of isovolumic relaxation (tau), maximum segment lengthening velocity during rapid ventricular filling (dL/dtmax), and a regional chamber stiffness constant (Kp). Dogs were randomly assigned to receive levosimendan (0.5, 1.0, 2.0, and 4.0 micrograms.kg-1.min-1) with or without ANS blockade. On separate experimental days, systemic and coronary hemodynamics and LV pressure-segment length diagrams and waveforms were recorded after 10-min equilibration at each dose in the conscious ANS-intact or ANS-blocked state. Levosimendan increased heart rate (HR), CO, mean and diastolic CBF velocity, and pressure-work index (PWI, an estimate of myocardial oxygen consumption) and decreased LV end-diastolic pressure (EDP), systemic vascular resistance (SVR), end-systolic and end-diastolic segment length, and mean and diastolic coronary vascular resistance (CVR) in dogs with intact ANS function. Levosimendan-induced increases in HR and PWI and decreases in SVR were attenuated by ANS blockade. Levosimendan caused equivalent dose-dependent increases in Mw in ANS-intact and ANS-blocked dogs, consistent with a positive inotropic effect independent of ANS activity. Levosimendan decreased tau (e.g., 35 +/- 1 ms during control to 29 +/- 1 ms at the high dose) and increased the magnitude of LV -dP/dtmin in dogs with intact but not blocked ANS reflexes, suggesting that relaxation was enhanced by favorable changes in systemic hemodynamics or ANS activation and direct effects of this drug on lusitropic state. Levosimendan also increased dL/dtmax to a greater degree in ANS-intact dogs, indicating that improvement of rapid ventricular filling was also partially dependent on ANS tone. No changes in Kp were observed in either experimental group. The results indicate that levosimendan decreases preload and afterload and has positive inotropic and lusitropic properties. The actions of levosimendan on diastolic function are largely mediated by the ANS.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7475041     DOI: 10.1097/00005344-199508000-00002

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  14 in total

1.  Cardiovascular profile of the calcium sensitizer EMD 57033 in open-chest anaesthetized pigs with regionally stunned myocardium.

Authors:  S de Zeeuw; S A Trines; R Krams; P D Verdouw; D J Duncker
Journal:  Br J Pharmacol       Date:  2000-04       Impact factor: 8.739

Review 2.  Drugs' development in acute heart failure: what went wrong?

Authors:  Vincenzo Teneggi; Nithy Sivakumar; Deborah Chen; Alex Matter
Journal:  Heart Fail Rev       Date:  2018-09       Impact factor: 4.214

3.  Levosimendan restores the positive force-frequency relation in heart failure.

Authors:  Satoshi Masutani; Heng-Jie Cheng; Hideo Tachibana; William C Little; Che-Ping Cheng
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-05-13       Impact factor: 4.733

4.  Comparison of the effects of levosimendan, pimobendan, and milrinone on canine left ventricular-arterial coupling and mechanical efficiency.

Authors:  P S Pagel; D A Hettrick; D C Warltier
Journal:  Basic Res Cardiol       Date:  1996 Jul-Aug       Impact factor: 17.165

5.  Influence of levosimendan, pimobendan, and milrinone on the regional distribution of cardiac output in anaesthetized dogs.

Authors:  P S Pagel; D A Hettrick; D C Warltier
Journal:  Br J Pharmacol       Date:  1996-10       Impact factor: 8.739

Review 6.  Levosimendan.

Authors:  D P Figgitt; P S Gillies; K L Goa
Journal:  Drugs       Date:  2001       Impact factor: 9.546

7.  Preoperative usages of levosimendan in patients undergoing coronary artery bypass grafting.

Authors:  Cuneyt Eris; Senol Yavuz; Faruk Toktas; Tamer Turk; Arif Gucu; Burak Erdolu; M Tugrul Goncu
Journal:  Int J Clin Exp Med       Date:  2014-01-15

8.  Beneficial effects of the Ca2+ sensitizer EMD 57033 in exercising pigs with infarction-induced chronic left ventricular dysfunction.

Authors:  D J Duncker; D B Haitsma; D A Liem; N Heins; R Stubenitsky; P D Verdouw
Journal:  Br J Pharmacol       Date:  2001-10       Impact factor: 8.739

9.  Levosimendan is superior to dobutamine as an inodilator in the treatment of pulmonary hypertension for children undergoing cardiac surgery.

Authors:  Abdelhay A Ebade; Mohamed A Khalil; Ahmed K Mohamed
Journal:  J Anesth       Date:  2012-12-09       Impact factor: 2.078

Review 10.  Levosimendan: a review of its use in the management of acute decompensated heart failure.

Authors:  Carmen A Innes; Antona J Wagstaff
Journal:  Drugs       Date:  2003       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.